As of late August 2025, Asian markets have shown mixed performance amid global economic uncertainties and regional developments. While China's stock markets have experienced a notable rally, concerns about slowing growth and potential stimulus measures remain prevalent. In this environment, companies with strong growth prospects and high insider ownership can be particularly appealing to investors seeking stability and alignment with management interests.
Top 10 Growth Companies With High Insider Ownership In Asia
| Name | Insider Ownership | Earnings Growth |
| Zhejiang Leapmotor Technology (SEHK:9863) | 14.6% | 56.0% |
| Suzhou Sunmun Technology (SZSE:300522) | 35.4% | 84.7% |
| Sineng ElectricLtd (SZSE:300827) | 36% | 27.6% |
| Seers Technology (KOSDAQ:A458870) | 34.1% | 84.6% |
| Novoray (SHSE:688300) | 23.6% | 29.8% |
| M31 Technology (TPEX:6643) | 30.7% | 96.8% |
| Laopu Gold (SEHK:6181) | 35.5% | 33.9% |
| Gold Circuit Electronics (TWSE:2368) | 31.4% | 35.2% |
| Fulin Precision (SZSE:300432) | 11.8% | 50.7% |
| Ascentage Pharma Group International (SEHK:6855) | 12.9% | 91.9% |
Here we highlight a subset of our preferred stocks from the screener.
Seers Technology (KOSDAQ:A458870)
Simply Wall St Growth Rating: ★★★★★★
Overview: Seers Technology Co., LTD. is a South Korean company offering telemedicine solutions with patient monitoring, and it has a market cap of ₩764.27 billion.
Operations: The company's revenue segments are not specified in the provided text.
Insider Ownership: 34.1%
Seers Technology is poised for significant growth, with revenue expected to increase by 52.2% annually, outpacing the broader Korean market's growth rate of 7.3%. Earnings are projected to grow at a robust 84.64% per year, and the company is anticipated to achieve profitability within three years. Despite high share price volatility recently, its forecasted return on equity of 31.5% in three years underscores strong potential amidst substantial insider ownership stability.
- Click here and access our complete growth analysis report to understand the dynamics of Seers Technology.
- The valuation report we've compiled suggests that Seers Technology's current price could be inflated.
Laopu Gold (SEHK:6181)
Simply Wall St Growth Rating: ★★★★★★
Overview: Laopu Gold Co., Ltd. designs, manufactures, and sells jewelry products in Mainland China, Hong Kong, and Macau with a market cap of HK$128.47 billion.
Operations: The company's revenue primarily comes from its Jewelry & Watches segment, which generated CN¥17.34 billion.
Insider Ownership: 35.5%
Laopu Gold demonstrates robust growth potential, with earnings forecasted to grow 33.9% annually, surpassing the Hong Kong market average. Revenue is projected to increase by 23.9% per year, indicating strong business momentum. Recent financial results showed significant profit and revenue increases compared to last year. Despite no recent insider trading activity, high insider ownership aligns management interests with shareholders'. A new dividend policy aims for balanced shareholder returns and prudent capital management amidst this growth trajectory.
- Dive into the specifics of Laopu Gold here with our thorough growth forecast report.
- Our valuation report here indicates Laopu Gold may be overvalued.
Fujian Wanchen Biotechnology GroupLtd (SZSE:300972)
Simply Wall St Growth Rating: ★★★★★★
Overview: Fujian Wanchen Biotechnology Group Ltd (SZSE:300972) focuses on the research, development, cultivation, production, and sale of edible fungi in China with a market capitalization of CN¥35.71 billion.
Operations: The company generates revenue primarily through its activities in research, development, cultivation, production, and sale of edible fungi within China.
Insider Ownership: 25.8%
Fujian Wanchen Biotechnology Group Ltd. shows promising growth prospects, with earnings projected to grow 38.84% annually, outpacing the Chinese market average. Revenue is expected to increase by 21% per year, supported by recent financial results showing substantial revenue and net income growth compared to last year. Despite no recent insider trading activity, high insider ownership ensures management's interests align with shareholders'. A recent stake acquisition further underscores confidence in the company's future trajectory.
- Click to explore a detailed breakdown of our findings in Fujian Wanchen Biotechnology GroupLtd's earnings growth report.
- Upon reviewing our latest valuation report, Fujian Wanchen Biotechnology GroupLtd's share price might be too optimistic.
Summing It All Up
- Click here to access our complete index of 606 Fast Growing Asian Companies With High Insider Ownership.
- Ready For A Different Approach? Rare earth metals are the new gold rush. Find out which 29 stocks are leading the charge.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Valuation is complex, but we're here to simplify it.
Discover if Fujian Wanchen Biotechnology GroupLtd might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com